Ninety (90) commercial clinical cases, thirty (30) for each of NSCLC (BioIVT, West Sussex, UK, ProteoGenex, Inc., Inglewood, CA, USA and Tissue Solutions, Glasgow, UK) HNSCC and UC (Avaden Biosciences, Seattle, WA, USA), previously assessed using the VENTANA PD-L1 (SP263) Assay (Ventana, Tucson, AZ) were chosen to represent a wide range of percentage tumour cell membrane staining (TCIHC). This tissue set has previously been assessed using other PD-L1 IHC assays such as Dako PD-L1 IHC 22C3 pharmDx and PD-L1 IHC 28–8 pharmDx assays [12 (link), 25 ]. Tissue cases included in the analysis represent samples that may be encountered in a routine clinical setting. Tissue was formalin fixed according to industry guidelines [26 (link)].
Tissue sections were cut at 4μm thickness. IHC and RNAScope assays were performed on tissue cut within 10 consecutive sections of each other, this minimises the impact of heterogeneity within a tissue block [27 (link)]. Tissue sections were assessed by IHC within 3 months of preparation. RNAScope staining was performed within 12 months of tissue sectioning [28 (link)].
Tissue sections were cut at 4μm thickness. IHC and RNAScope assays were performed on tissue cut within 10 consecutive sections of each other, this minimises the impact of heterogeneity within a tissue block [27 (link)]. Tissue sections were assessed by IHC within 3 months of preparation. RNAScope staining was performed within 12 months of tissue sectioning [28 (link)].
Free full text: Click here
